David T. Rubin to Quality of Life
This is a "connection" page, showing publications David T. Rubin has written about Quality of Life.
Connection Strength
2.051
-
Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. Dis Colon Rectum. 2019 04; 62(4):463-469.
Score: 0.363
-
The impact of ulcerative colitis on patients' lives compared to other chronic diseases: a patient survey. Dig Dis Sci. 2010 Apr; 55(4):1044-52.
Score: 0.187
-
The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis. 2024 Jun 03; 30(6):939-949.
Score: 0.130
-
Overview to Challenges in IBD 2024-2029. Inflamm Bowel Dis. 2024 May 23; 30(Supplement_2):S1-S4.
Score: 0.130
-
Treat-to-target and sequencing therapies in Crohn's disease. United European Gastroenterol J. 2022 12; 10(10):1121-1128.
Score: 0.117
-
Ulcerative Colitis Patients Have Reduced Rectal Compliance Compared With Non-Inflammatory Bowel Disease Controls. Gastroenterology. 2022 01; 162(1):331-333.e1.
Score: 0.108
-
Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology. 2021 10; 161(4):1118-1132.
Score: 0.107
-
Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians. Inflamm Bowel Dis. 2021 06 15; 27(7):1096-1106.
Score: 0.106
-
Burden of comorbid anxiety and depression in patients with inflammatory bowel disease: a systematic literature review. Expert Rev Gastroenterol Hepatol. 2021 Sep; 15(9):985-997.
Score: 0.106
-
Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey. J Crohns Colitis. 2018 Apr 27; 12(5):600-609.
Score: 0.085
-
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24; 12(2):145-156.
Score: 0.084
-
Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits. Inflamm Bowel Dis. 2017 04; 23(4):494-501.
Score: 0.079
-
Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013 Oct; 19(11):2440-3.
Score: 0.062
-
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. Aliment Pharmacol Ther. 2011 Mar; 33(6):672-8.
Score: 0.051
-
Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study. Dig Dis Sci. 2024 Jul; 69(7):2333-2344.
Score: 0.032
-
Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis. 2023 09 01; 29(9):1370-1379.
Score: 0.031
-
Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions. Am J Gastroenterol. 2023 11 01; 118(11):1940-1953.
Score: 0.030
-
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
Score: 0.028
-
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clin Gastroenterol Hepatol. 2022 11; 20(11):2619-2627.e1.
Score: 0.028
-
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2021 10; 6(10):826-849.
Score: 0.027
-
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 04; 160(5):1570-1583.
Score: 0.026
-
Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
Score: 0.025
-
An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI. Clin Gastroenterol Hepatol. 2021 12; 19(12):2524-2531.
Score: 0.025
-
Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424.
Score: 0.020
-
Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017 Apr 01; 11(4):400-411.
Score: 0.020
-
Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther. 2017 01; 45(2):264-275.
Score: 0.019
-
Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013 Mar; 19(3):662-8.
Score: 0.015
-
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41.
Score: 0.011